KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Operating Leases (2019 - 2025)

Astrana Health's Operating Leases history spans 7 years, with the latest figure at $30.2 million for Q3 2025.

  • For Q3 2025, Operating Leases fell 3.18% year-over-year to $30.2 million; the TTM value through Sep 2025 reached $30.2 million, down 3.18%, while the annual FY2024 figure was $30.7 million, 15.53% down from the prior year.
  • Operating Leases for Q3 2025 was $30.2 million at Astrana Health, up from $29.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $42.7 million in Q1 2024 and bottomed at $12.6 million in Q1 2022.
  • The 5-year median for Operating Leases is $20.5 million (2022), against an average of $23.1 million.
  • The largest annual shift saw Operating Leases soared 135.21% in 2024 before it crashed 32.21% in 2025.
  • A 5-year view of Operating Leases shows it stood at $13.2 million in 2021, then skyrocketed by 50.89% to $19.9 million in 2022, then skyrocketed by 82.22% to $36.3 million in 2023, then fell by 15.53% to $30.7 million in 2024, then decreased by 1.58% to $30.2 million in 2025.
  • Per Business Quant, the three most recent readings for ASTH's Operating Leases are $30.2 million (Q3 2025), $29.0 million (Q1 2025), and $30.7 million (Q4 2024).